Clinical trials: Stage III Prostate Adenocarcinoma
Prostate Cancer, Adenocarcinoma
A Long Term Safety Study With Atrasentan
The primary purpose of the study is to evaluate long-term safety and tolerability of atrasentan 10 mg in men with hormone refractory prostate cancer.
- Trial name
- NCT00127478
- Testing
- Atrasentan
- Where
- 15 sites in United States, Canada and 3 more
- Volunteers
- 166 people
- Sponsor
- Abbott
Prostate Cancer
Pomegranate Extract in Treating Patients With Rising Prostate-Specific Antigen Levels After Surgery or Radiation Therapy for Localized Prostate Cancer
RATIONALE: Pomegranate extract may keep prostate cancer from growing in patients with rising prostate-specific antigen (PSA) levels after surgery or radiation therapy for localized prostate cancer.
- Trial name
- NCT00336934
- Testing
- pomegranate juice
- Volunteers
- 183 people
- Sponsor
- Roll International Corporation
Cancer
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
RATIONALE: VEGF Trap may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and best dose of intravenous VEGF Trap in treating…
- Trial name
- NCT00083213
- Testing
- ziv-aflibercept
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Regeneron Pharmaceuticals
Cancer
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
RATIONALE: Intravenous VEGF Trap may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping blood flow to the cancer.
- Trial name
- NCT00082823
- Testing
- ziv-aflibercept
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Regeneron Pharmaceuticals
Prostate Cancer
Atrasentan in Treating Patients With Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase III trial to determine the effectiveness of atrasentan in treating patients who have prostate…
- Trial name
- NCT00046943
- Testing
- atrasentan hydrochloride
- Where
- United States
- Sponsor
- Abbott
Prostate Cancer, Adenocarcinoma of the Prostate
Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Men With Advanced Prostate Cancer
Objective was to evaluate the efficacy and safety of the histrelin acetate subdermal implant (originally versus Lupron Depot-3 Month) in male patients with advanced prostate cancer during 52 weeks of treatment with the implant.
- Trial name
- NCT01697384
- Testing
- histrelin acetate
- Volunteers
- 138 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Prostate Cancer
Liposomal Doxorubicin and Thermal Therapy in Treating Patients With Prostate Cancer
RATIONALE: Drugs used in chemotherapy, such as liposomal doxorubicin, use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00061867
- Testing
- pegylated liposomal doxorubicin hydrochloride, hyperthermia treatment
- Where
- 2 sites in United States
- Sponsor
- Imunon
HER2-positive Breast Cancer, HER2 Gene Mutation
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Open-label, Phase I-II, first-in-human (FIH) study for A166 monotherapy in HER2-expressing or amplified patients who progressed on or did not respond to available standard therapies.
- Conditions
- HER2-positive Breast Cancer, HER2 Gene Mutation, HER-2 Gene Amplification, HER2 Positive Gastric Cancer
- Trial name
- NCT03602079
- Testing
- A166
- Where
- 10 sites in United States
- Volunteers
- 49 people
- Sponsor
- Klus Pharma Inc.
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Pain, Prostate Cancer
Combination Chemotherapy in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug may kill more tumor cells.
- Trial name
- NCT00005960
- Testing
- filgrastim, cyclophosphamide, docetaxel
- Where
- 6 sites in United States
- Sponsor
- Amgen
Solid Tumors Stage II, Stage III and Stage IV, Breast Cancer
Experimental Therapeutic Cancer Vaccine Created In-situ in Patients With Stage II-Stage IV Cancer
A Phase I/II study of an in-situ therapeutic cancer vaccine. Vaccines contain a source of antigen and and adjuvant. In this study the source of tumor antigen comes from the killing of a selected tumor by cryoablation (killing…
- Conditions
- Solid Tumors Stage II, Stage III and Stage IV, Breast Cancer, Colorectal Cancer, Prostate Cancer
- Trial name
- NCT01065441
- Testing
- AlloStim, Cryoablation
- Where
- Israel
- Volunteers
- 9 people
- Sponsor
- Michael Har-Noy
Stage III Breast Cancer, Stage IV Breast Cancer
Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
The primary objective of this study, sponsored by Travera in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using…
- Conditions
- Stage III Breast Cancer, Stage IV Breast Cancer, Stage III Lung Cancer, Stage IV Lung Cancer
- Trial name
- NCT04985357
- Sponsor
- Travera Inc
Prostate Cancer, Adenocarcinoma of the Prostate
Study of Histrelin Subdermal Implant in Patients With Prostate Cancer
This trial was an open-label, multi-national, randomized, parallel treatment, active-control multicenter study in adult males with documented metastatic prostate cancer disease who were judged to be candidates for hormone therapy.
- Trial name
- NCT01394263
- Testing
- Histrelin hydrogel implant, Zoladex goserelin implant
- Volunteers
- 59 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company